Ikarian Capital’s Jade Biosciences JBIO Stock Holding History

Ikarian Capital’s Portfolio JBIO Stock Details JBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.5M	Sell	427,349 -85,000	-17%	-$1.77M	1.02%	29
2026 Q1	$7.2M	Buy	512,349 +212,349	+71%	+$3.07M	0.58%	47
2025 Q4	$4.63M	Buy	+300,000	New	+$3.52M	0.36%	65
2024 Q4	–	Sell	-10,513	Closed	-$769K	–	177
2024 Q3	$769K	Hold	10,513	–	–	0.11%	108
2024 Q2	$611K	Hold	10,513	–	–	0.11%	89
2024 Q1	$10.9M	Buy	+10,513	New	+$8.03M	1.19%	23
2023 Q2	–	Sell	-5,576	Closed	-$3.94M	–	134
2023 Q1	$3.94M	Buy	5,576 +1,921	+53%	+$1.59M	0.89%	41
2022 Q4	$3.75M	Sell	3,655 -2,059	-36%	-$1.49M	0.9%	34
2022 Q3	$3.32M	Buy	+5,714	New	+$3.81M	0.66%	47

Other funds holding JBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ikarian Capital's JBIO Position: Q2 2026 in Review

Ikarian Capital reduced its Jade Biosciences (JBIO) stake by 17% in Q2 2026, selling an estimated $1.77M and leaving 427,349 shares worth $9.5M. The position accounts for 1.02% of the portfolio, ranked #29.

Ikarian Capital first reported a position in JBIO in Q3 2022 and has held it in 9 quarters since. The position peaked at $10.9M in Q1 2024. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

Ikarian Capital held 427,349 shares of Jade Biosciences worth $9.5M as of Q2 2026.
Ikarian Capital sold 85,000 Jade Biosciences shares in Q2 2026, an estimated $1.77M.
Jade Biosciences made up 1.02% of Ikarian Capital's portfolio in Q2 2026, its #29 holding.
Ikarian Capital first reported a position in Jade Biosciences in Q3 2022 and has held it in 9 quarters since.
Ikarian Capital's Jade Biosciences position peaked at $10.9M in Q1 2024.
154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.